CA2477221A1 - Simple tablet compression using gelatin - Google Patents
Simple tablet compression using gelatin Download PDFInfo
- Publication number
- CA2477221A1 CA2477221A1 CA002477221A CA2477221A CA2477221A1 CA 2477221 A1 CA2477221 A1 CA 2477221A1 CA 002477221 A CA002477221 A CA 002477221A CA 2477221 A CA2477221 A CA 2477221A CA 2477221 A1 CA2477221 A1 CA 2477221A1
- Authority
- CA
- Canada
- Prior art keywords
- tablet
- gelatin
- powder
- disintegrator
- diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention comprises a method of tablet preparation. The inventio n provides a simple and cost effective method to compress good tablets.</SDOAB >
Description
SIMPLE TABLET COMPRESSION USING GELATIN
FIELD OF THE INVENTION
This invention relates to tablet preparations.
BACKGROUND OF THE INVENTION
In addition to the active ingredient(s), a tablet basically contains: (1) diluent, (2) binder, (3) disintegrator, and (4) lubricant.
Diluent is a substance or a mixtuxe of substances added to a tablet to increase the bulk in order to make the tablet a practical size for compression.
Binder is a substance or a mixture of substances added to a tablet to impart a cohesiveness to the tablet formulation which insures the tablet remaining intact after compression.
Disintegrator is a substance or a mixture of substances added to a tablet to facilitate its breakup or disintegration after administration.
Lubricant is a substance or a mixture of substances added to a tablet to improve the flowability and to prevent adhesion of the tablet material to the surface of the dies and punches, reduce interparticle friction, and facilitate the ejection of the tablets from the die cavity.
There are currently three general methods of tablet preparation: (1) wet-granulation method, (2) dry-granulation method, and (3) direct compression. All three methods have disadvantages.
Wet-granulation method is the most widely used method. Its popularity is due to the greater probability that the granulation will meet all the physical requirements for the compression of good tablets. Its chief disadvantages are the number of separate steps involved and the time and labor necessary to carry out the procedure. The steps involved in the wet-granulation method are: (1) weighing, (2) mixing, (3) granulation, (4) screening the damp mass after granulation, (5) drying (6) dry screening (7) lubrication, and (8) compression.
Dry-granulation method is generally used when tablet ingredients are sensitive to moisture or are unable to withstand elevated temperatures during drying. This method eliminates a number of steps but still includes (1) weighing, (2) mixing, (3) dry granulation, (4) dry screening, (5) lubrication, and (6) compression. However, this method requires that the tablet ingredients must have sufficient inherent binding or cohesive properties for dry granulation.
Direct compression consists of compressing tablets directly from ingredients without wet or dry granulation. This method comprises only three steps: (1) weighing, (2) mixing, and (3) compression. However, it has two major disadvantages: (1) the active ingredients must possess inherent binding and cohesive properties, and/or (2) the diluents and/or binders must be capable of imparting the compressible characteristics. To acquire these properties, the ingredients must be subjected to preprocessing step such as wet granulation, dry granulation, or other granulation processes such as spheronization, spray drying, and crystallization.
SUMMARY OF INVENTION
The present invention discloses a new method of tablet preparation which is very simple and cost effective.
The method of the present invention consists of compressing tablets directly from powdered materials without modifying the physical nature of the materials using gelatin. All ingredients used in this method do not have to undergo preprocessing step such as wet granulation, dry granulation, or other granulation processes such as spheronization, spray drying, and crystallization.
An aqueous solution of gelatin has often been used in wet granulation.
However, its dry form, powder or granules, has never been directly used in tablet compression .
It is an object of this invention to provide a simple method of preparing tablets in which gelatin, in its dry form, with its strong binding, cohesive, and hydrophillic properties, can be utilized as tablet diluent, and/or binder, andlor disintegrator.
The method of tablet preparation in this invention comprises only three simple steps: (1) weighing, (2) mixing, and (3) compression.
DETAIL DESCRIPTION OF THE INVENTION
The following discussion details procedure of the tablet preparation using gelatin.
Gelatin used in this invention can be powder or granules and in concentrations from 0.1 % to i 99.9% of the tablet weight.
STEP 1- WEIGHING: Active ingredient(s), gelatin, and other ingredients) are accurately weighed.
STEP 2- MIXING: Active ingredient(s), gelatin, and other ingredients) are added, one item at a time, into a suitable blender and mix for an appropriate length of time.
STEP 3- COMPRESSION: The mixture from STEP 2 is compressed into tablets.
In order to more clearly define the invention, the following examples of method of preparing tablets using gelatin at different concentrations are given. It is understood that these examples are considered as illustrative only and are not to be construed as limitations on the present invention.
EXAMpLFJ I: Gelatin is used as diluent, binder, and disintegrator Vitamin E12 6 mcg tablets Vitamin BIZ, powder (active ingredient) 0.006 mg/tablet Gelatine, powder 199.804 mg/tablet Magnesium stearate, powder (lubricant) 0.190 mg/tablet Total Weight 200.000 mg/tablet Procedure 1. Accurately weigh vitamin Blz, gelatin, and magnesium stearate.
FIELD OF THE INVENTION
This invention relates to tablet preparations.
BACKGROUND OF THE INVENTION
In addition to the active ingredient(s), a tablet basically contains: (1) diluent, (2) binder, (3) disintegrator, and (4) lubricant.
Diluent is a substance or a mixtuxe of substances added to a tablet to increase the bulk in order to make the tablet a practical size for compression.
Binder is a substance or a mixture of substances added to a tablet to impart a cohesiveness to the tablet formulation which insures the tablet remaining intact after compression.
Disintegrator is a substance or a mixture of substances added to a tablet to facilitate its breakup or disintegration after administration.
Lubricant is a substance or a mixture of substances added to a tablet to improve the flowability and to prevent adhesion of the tablet material to the surface of the dies and punches, reduce interparticle friction, and facilitate the ejection of the tablets from the die cavity.
There are currently three general methods of tablet preparation: (1) wet-granulation method, (2) dry-granulation method, and (3) direct compression. All three methods have disadvantages.
Wet-granulation method is the most widely used method. Its popularity is due to the greater probability that the granulation will meet all the physical requirements for the compression of good tablets. Its chief disadvantages are the number of separate steps involved and the time and labor necessary to carry out the procedure. The steps involved in the wet-granulation method are: (1) weighing, (2) mixing, (3) granulation, (4) screening the damp mass after granulation, (5) drying (6) dry screening (7) lubrication, and (8) compression.
Dry-granulation method is generally used when tablet ingredients are sensitive to moisture or are unable to withstand elevated temperatures during drying. This method eliminates a number of steps but still includes (1) weighing, (2) mixing, (3) dry granulation, (4) dry screening, (5) lubrication, and (6) compression. However, this method requires that the tablet ingredients must have sufficient inherent binding or cohesive properties for dry granulation.
Direct compression consists of compressing tablets directly from ingredients without wet or dry granulation. This method comprises only three steps: (1) weighing, (2) mixing, and (3) compression. However, it has two major disadvantages: (1) the active ingredients must possess inherent binding and cohesive properties, and/or (2) the diluents and/or binders must be capable of imparting the compressible characteristics. To acquire these properties, the ingredients must be subjected to preprocessing step such as wet granulation, dry granulation, or other granulation processes such as spheronization, spray drying, and crystallization.
SUMMARY OF INVENTION
The present invention discloses a new method of tablet preparation which is very simple and cost effective.
The method of the present invention consists of compressing tablets directly from powdered materials without modifying the physical nature of the materials using gelatin. All ingredients used in this method do not have to undergo preprocessing step such as wet granulation, dry granulation, or other granulation processes such as spheronization, spray drying, and crystallization.
An aqueous solution of gelatin has often been used in wet granulation.
However, its dry form, powder or granules, has never been directly used in tablet compression .
It is an object of this invention to provide a simple method of preparing tablets in which gelatin, in its dry form, with its strong binding, cohesive, and hydrophillic properties, can be utilized as tablet diluent, and/or binder, andlor disintegrator.
The method of tablet preparation in this invention comprises only three simple steps: (1) weighing, (2) mixing, and (3) compression.
DETAIL DESCRIPTION OF THE INVENTION
The following discussion details procedure of the tablet preparation using gelatin.
Gelatin used in this invention can be powder or granules and in concentrations from 0.1 % to i 99.9% of the tablet weight.
STEP 1- WEIGHING: Active ingredient(s), gelatin, and other ingredients) are accurately weighed.
STEP 2- MIXING: Active ingredient(s), gelatin, and other ingredients) are added, one item at a time, into a suitable blender and mix for an appropriate length of time.
STEP 3- COMPRESSION: The mixture from STEP 2 is compressed into tablets.
In order to more clearly define the invention, the following examples of method of preparing tablets using gelatin at different concentrations are given. It is understood that these examples are considered as illustrative only and are not to be construed as limitations on the present invention.
EXAMpLFJ I: Gelatin is used as diluent, binder, and disintegrator Vitamin E12 6 mcg tablets Vitamin BIZ, powder (active ingredient) 0.006 mg/tablet Gelatine, powder 199.804 mg/tablet Magnesium stearate, powder (lubricant) 0.190 mg/tablet Total Weight 200.000 mg/tablet Procedure 1. Accurately weigh vitamin Blz, gelatin, and magnesium stearate.
2. Mix vitamin BIZ and gelatin in a suitable blender for 15 minutes. Add magnesium stearate and mix for additional 5 minutes.
3. Compress.
Tablet properties Size/Form: 0.291" round tablet Weight: 200.0 mg Hardness: 5.0 Kg Friability: Less than 1.0%
Disintegration:1 minute EXAMPLE II: Gelatin is used as diluent, binder, and disintegrator Vitamins-minerals-herbs tablets Thiamin HCI, powder (active ingredient)10.00 mg/tablet Niacinamide, powder (active ingredient)20.00 mg/tablet Pyridoxine HCI, powder (active 10.00 mg/tablet ingredient) Calcium carbonate, powder (active 525.00 mg/tablet ingredient) Magnesium oxide, powder (active ingredient) 335.00 mg/tablet Green tea, powder (active ingredient) 10.00 mg/tablet Korean ginseng, powder (active ingredient) 20.00 mg/tablet Gelatine, powder 100.00 mg/tablet Magnesium stearate, powder (lubricant) 20.00 mg/tablet Silicon dioxide, powder (lubricant) 10.00 mg/tablet Total Weight 1060.00 mg/tablet Procedure 1. Accurately weigh thiamin HCI, niacinamide, pyridoxine HC1, calcium carbonate, magnesium oxide, green tea, Korean ginseng, gelatin, magnesium stearate, and silicon dioxide.
2. Add thiamin HCI, niacinamide, pyridoxine HCI, calcium carbonate, magnesium oxide, green tea, Korean ginseng, gelatin, one item at a time, in a suitable blender and mix for 15 minutes. Add magnesium steaxate and silicon dioxide and mix for additional minutes.
3. Compress.
Tablet properties Size/Form: 5/8" round tablet Weight: 1060.0 mg Hardness: 8.0 Kg Friability: Less than 1.0%
Disintegration:10 minutes EXAMPLE III: Gelatin is used as diluent and binder Potassium chloride 30 mg tablets Potassium chloride, powder (active ingredient) 30.0 mg/tablet Gelatin, powder 160.0 mg/tablet Croscarmelose sodium, powder (disintegrator) 2.0 mg/tablet Talc, powder (lubricant) 5.0 mg/tablet Magnesium stearate, powder (lubricant) 3.0 mg/tablet Total Weight 200.0 mg/tablet Procedure 1. Accurately weigh potassium chloride, gelatin, croscarmelose sodium, talc, and magnesium stearate.
2. Add potassium chloride, gelatin, and croscarmelose sodium, one item at a time, in a suitable blender and mix for 15 minutes. Add talc and magnesium steaxate and mix for additional 5 minutes.
3. Compress.
Tablet properties Size/Form: 0.291" round tablet Weight: 200.0 mg Hardness: 5.0 Kg Friability: Less than 1.0%
Disintegration:1 minute EXAMPLE II: Gelatin is used as diluent, binder, and disintegrator Vitamins-minerals-herbs tablets Thiamin HCI, powder (active ingredient)10.00 mg/tablet Niacinamide, powder (active ingredient)20.00 mg/tablet Pyridoxine HCI, powder (active 10.00 mg/tablet ingredient) Calcium carbonate, powder (active 525.00 mg/tablet ingredient) Magnesium oxide, powder (active ingredient) 335.00 mg/tablet Green tea, powder (active ingredient) 10.00 mg/tablet Korean ginseng, powder (active ingredient) 20.00 mg/tablet Gelatine, powder 100.00 mg/tablet Magnesium stearate, powder (lubricant) 20.00 mg/tablet Silicon dioxide, powder (lubricant) 10.00 mg/tablet Total Weight 1060.00 mg/tablet Procedure 1. Accurately weigh thiamin HCI, niacinamide, pyridoxine HC1, calcium carbonate, magnesium oxide, green tea, Korean ginseng, gelatin, magnesium stearate, and silicon dioxide.
2. Add thiamin HCI, niacinamide, pyridoxine HCI, calcium carbonate, magnesium oxide, green tea, Korean ginseng, gelatin, one item at a time, in a suitable blender and mix for 15 minutes. Add magnesium steaxate and silicon dioxide and mix for additional minutes.
3. Compress.
Tablet properties Size/Form: 5/8" round tablet Weight: 1060.0 mg Hardness: 8.0 Kg Friability: Less than 1.0%
Disintegration:10 minutes EXAMPLE III: Gelatin is used as diluent and binder Potassium chloride 30 mg tablets Potassium chloride, powder (active ingredient) 30.0 mg/tablet Gelatin, powder 160.0 mg/tablet Croscarmelose sodium, powder (disintegrator) 2.0 mg/tablet Talc, powder (lubricant) 5.0 mg/tablet Magnesium stearate, powder (lubricant) 3.0 mg/tablet Total Weight 200.0 mg/tablet Procedure 1. Accurately weigh potassium chloride, gelatin, croscarmelose sodium, talc, and magnesium stearate.
2. Add potassium chloride, gelatin, and croscarmelose sodium, one item at a time, in a suitable blender and mix for 15 minutes. Add talc and magnesium steaxate and mix for additional 5 minutes.
3. Compress.
Tablet properties Size/Form: 0.291" round tablet Weight: 200.0 mg Hardness: 7.0 Kg Friability: Less than 1.0%
Disintegration:2 minutes EXAMPLE IV: Gelatin is used as binder Calcium carbonate 1250 mg tablets Calcium carbonate, powder (active ingredient) 1250.0 mg/tablet Gelatine, powder 80.0 mg/tablet Stearic acid, powder (diluent) 40.0 mg/tablet Microcrystalline cellulose, powder (diluent) 35.0 mg/tablet Croscannelose sodium, powder (disintegrator) 35.0 mg/tablet Magnesium stearate, powder (lubricant) 30.0 mg/tablet Silicon dioxide, powder (lubricant) 15.0 mg/tablet Total Weight 1485.0 mg/tablet Procedure 1. Accurately weigh calcium carbonate, gelatin, stearic acid, microcrystalline cellulose, croscannelose sodium, magnesium stearate, and silicon dioxide.
2. Add calcium carbonate, gelatin, stearic acid, microcrystalline cellulose, croscarmelose sodium, one item at a time, in a suitable blender and mix for 15 minutes. Add magnesium stearate and silicon dioxide and mix for additional 5 minutes.
3. Compress.
Tablet properties Size/Form: 0.750 x 0.312" caplet Weight: 1485.0 mg Hardness: 8.0 Kg Friability: Less than 1.0%
Disintegration: 5 minutes EXAMPLE V : Gelatin is used as disintegrator Methenamine 500 mg tablets Methenamine, powder (active ingredient) 500.0 mg/tablet Gelatine, powder 0.5 mg/tablet Magnesium stearate, powder (lubricant) 4.5 mg/tablet Total Weight 505.0 mg/tablet Procedure 1. Accurately weigh methenamine, gelatin, and magnesium stearate.
2. Mix methenamine and gelatin in a suitable blender for 15 minutes. Add magnesium stearate and mix for additional 5 minutes.
3. Compress.
s Tablet properties Size/Form: 3/8" round tablet Weight: 505.0 mg Hardness: 5.0 Kg Friability: Less than 1.0%
Disintegration: 5 minutes Note: In this example, methenamine naturally possesses cohesive property which makes compression without binders possible. However, if gelatin is absent, the disintegration would take longer than 30 minutes.
Disintegration:2 minutes EXAMPLE IV: Gelatin is used as binder Calcium carbonate 1250 mg tablets Calcium carbonate, powder (active ingredient) 1250.0 mg/tablet Gelatine, powder 80.0 mg/tablet Stearic acid, powder (diluent) 40.0 mg/tablet Microcrystalline cellulose, powder (diluent) 35.0 mg/tablet Croscannelose sodium, powder (disintegrator) 35.0 mg/tablet Magnesium stearate, powder (lubricant) 30.0 mg/tablet Silicon dioxide, powder (lubricant) 15.0 mg/tablet Total Weight 1485.0 mg/tablet Procedure 1. Accurately weigh calcium carbonate, gelatin, stearic acid, microcrystalline cellulose, croscannelose sodium, magnesium stearate, and silicon dioxide.
2. Add calcium carbonate, gelatin, stearic acid, microcrystalline cellulose, croscarmelose sodium, one item at a time, in a suitable blender and mix for 15 minutes. Add magnesium stearate and silicon dioxide and mix for additional 5 minutes.
3. Compress.
Tablet properties Size/Form: 0.750 x 0.312" caplet Weight: 1485.0 mg Hardness: 8.0 Kg Friability: Less than 1.0%
Disintegration: 5 minutes EXAMPLE V : Gelatin is used as disintegrator Methenamine 500 mg tablets Methenamine, powder (active ingredient) 500.0 mg/tablet Gelatine, powder 0.5 mg/tablet Magnesium stearate, powder (lubricant) 4.5 mg/tablet Total Weight 505.0 mg/tablet Procedure 1. Accurately weigh methenamine, gelatin, and magnesium stearate.
2. Mix methenamine and gelatin in a suitable blender for 15 minutes. Add magnesium stearate and mix for additional 5 minutes.
3. Compress.
s Tablet properties Size/Form: 3/8" round tablet Weight: 505.0 mg Hardness: 5.0 Kg Friability: Less than 1.0%
Disintegration: 5 minutes Note: In this example, methenamine naturally possesses cohesive property which makes compression without binders possible. However, if gelatin is absent, the disintegration would take longer than 30 minutes.
Claims (10)
1. A simple method for directly compressing tablets, consisting of compressing tablets directly from powdered materials without modifying the physical nature of the materials using gelatin wherein said powdered materials do not undergo a preprocessing step.
2. The method of claim 1, wherein said gelatin can be powder or granules.
3. The method of claim 1, wherein said gelatin is used in concentrations from 0. i °f° to 99.9% of the tablet weight.
4. The method of claim 1, wherein said gelatin is used as diluent, binder, and disintegrator.
5. The method of claim 1, wherein said gelatin is used as diluent and binder..
6. The methad of claim 1, wherein said gelatin is used as diluent and disintegrator.
7. The method of claim 1, wherein said gelatin is used as binder and disintegrator.
8. The method of claim 1, wherein said gelatin is used as diluent.
9. The method of claim 19 wherein said gelatin is used as binder.
10. The method of claim 1, wherein said gelatin is used as disintegrator.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2003/002945 WO2004062647A1 (en) | 2003-01-03 | 2003-01-03 | Simple tablet compression using gelatin |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2477221A1 true CA2477221A1 (en) | 2004-07-29 |
Family
ID=32710277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002477221A Abandoned CA2477221A1 (en) | 2003-01-03 | 2003-01-03 | Simple tablet compression using gelatin |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1587501A4 (en) |
AU (1) | AU2003208918A1 (en) |
CA (1) | CA2477221A1 (en) |
WO (1) | WO2004062647A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4140192C2 (en) * | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-controlled gelatin-based thermocolloid matrix for peroral sustained release forms |
HUP9802086A3 (en) * | 1995-02-28 | 2001-02-28 | Aventis Pharmaceuticals Inc Br | Pharmaceutical composition for piperidinoalkanol compounds |
US5958455A (en) * | 1996-02-09 | 1999-09-28 | Quadrant Holdings Cambridge Ltd | Oral solid dosage forms, methods of making same and compositions thereof |
-
2003
- 2003-01-03 CA CA002477221A patent/CA2477221A1/en not_active Abandoned
- 2003-01-03 EP EP03707641A patent/EP1587501A4/en not_active Withdrawn
- 2003-01-03 AU AU2003208918A patent/AU2003208918A1/en not_active Abandoned
- 2003-01-03 WO PCT/US2003/002945 patent/WO2004062647A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1587501A4 (en) | 2007-04-11 |
AU2003208918A1 (en) | 2004-08-10 |
WO2004062647A1 (en) | 2004-07-29 |
EP1587501A1 (en) | 2005-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4036948A (en) | L-ascorbic acid tablets | |
Bos et al. | Native starch in tablet formulations: properties on compaction | |
KR100384264B1 (en) | Manufacturing method of dosage unit by wet granulation | |
US5104648A (en) | High ibuprofen content granulations | |
SA517390473B1 (en) | Solid dosage forms of palbociclib | |
JPH0696523B2 (en) | Granular N-acetyl-P-aminophenol composition and method for producing the same | |
NZ277790A (en) | Paroxetine formulation as tablets which are made without water in the process | |
JP2008543767A5 (en) | ||
AU629913B2 (en) | High ibuprofen content granulations | |
TW201023897A (en) | Directly compressible granular microcrystalline cellulose based excipient, manufacturing process and use thereof | |
WO2013082706A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
KR20040063900A (en) | Extended release pharmaceutical composition containing metformin | |
US6569454B2 (en) | Simple tablet compression using gelatin | |
Herman et al. | Instability of drug release from anhydrous theophylline-imcrocrystalline cellulose formulations | |
Schwartz et al. | Intragranular starch: Comparison of starch USP and modified cornstarch | |
CA2415630A1 (en) | Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient | |
CA1036938A (en) | Direct compression diluent | |
JP4812211B2 (en) | Low dose tablets and methods of preparation | |
CA2477221A1 (en) | Simple tablet compression using gelatin | |
WO2020098904A1 (en) | Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor | |
EP1458384A1 (en) | Amlopidine bezylate tablets with improved stability | |
UA72270C2 (en) | Pharmaceutical composition containing ciprofloxacin and method for its manufacture | |
US3740432A (en) | Vitamin complexes of niacinamide,riboflavin and sodium ascorbate | |
EP0861069A1 (en) | Co-processing method for making a free-flowing compressible powder and tablet therefrom | |
AU632376B2 (en) | Pressing not delayed release of active compound, process for its production and use of polyhydroxybutyric acid for the production of such a pressing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |